Tvardi Therapeutics
TVRD
Tvardi Therapeutics (TVRD) news
Recent news
TVardi Therapeutics, - Phase 1 study of TTI-109 shows predictable pharmacokinetics and favorable GI tolerability
Tvardi Therapeutics (NASDAQ: TVRD) has released results from the Phase 1 clinical trial of its next-generation STAT3 inhibitor, TTI-109, demonstrating predictable pharmacokinetics and favorable gastrointestinal (GI) tolerability compared to its predecessor, TTI-101. The study, conducted in healthy…
AInvest Wire · Sep 24, 2026Tvardi Therapeutics - increases at-the-market offering program to $9.69 mln in shares - SEC filing
AInvest Wire · Jul 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.